Q-omics provides the consensus-scored AMMECR1LP1 profile across patient tissues and cancer cell-line models. AMMECR1LP1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, AMMECR1LP1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, AMMECR1LP1 RNA expression shows 10,546 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight LUAD, KICH, and PCPG as cancer lineages where AMMECR1LP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMMECR1LP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMMECR1LP1 survival associations across molecular data types. AMMECR1LP1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMMECR1LP1 RNA expression–survival associations across cancer types. High AMMECR1LP1 expression shows unfavorable associations in LUAD, KIRP, OV and THCA, but favorable associations in ACC and KICH. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for AMMECR1LP1 RNA expression.
This table summarizes AMMECR1LP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for AMMECR1LP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMMECR1LP1 shows lower tumor expression in UCEC and STAD and higher tumor expression in KICH, BRCA, BLCA and LUSC. The KICH box plot shows higher AMMECR1LP1 RNA expression in tumor versus normal tissue (log2 FC = +0.108, t-test p = .005).
This table shows molecular features associated with AMMECR1LP1 in patient tissues and cancer cell lines. In patient samples, AMMECR1LP1 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
